Trial Profile
A Phase 2, Open-label Multi-center Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Apremilast in Subjects With Recalcitrant Plaque-type Psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Amgen; Celgene Corporation
- 02 Sep 2009 Actual end date (May 2009) and actual number of patients (31) added as reported by ClinicalTrials.gov.
- 02 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2009 Planned end date changed from 1 May 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.